May 17, 2020

Meet the 9 Richest Health Care Professionals in Brazil

Hospital Leadership
Brazil
Health Care Professionals
Hospital Leadership
Admin
3 min
There are a number of wealthy individuals and families in Brazil. But who are the top earners working in the health care industry?
The richest people in Brazil make up a combined worth of R$ 643.6 billion ($274.6 billion) and a handful of those individuals work in the health care in...

The richest people in Brazil make up a combined worth of R$ 643.6 billion ($274.6 billion) and a handful of those individuals work in the health care industry. Here are the nine richest health care professionals in Brazil.

9. Antonio Carlos Pipponzi – R$ 1 billion ($427 million)

Antonio Carlos Pipponzi serves as President and CEO of Raia Drogasil SA – the fourth largest chain of drugstores in Brazil and second largest in the state of São Paulo.

8. Carlos Pires de Oliveira Dias – R$ 1.03 billion ($440 million)

Carlos Pires de Oliveira Dias is a board member of the pharmacy network Raia Drogasil. He graduated in economics from Mackenzie University.

7. Geninho Thome – R$ 1.16 billion ($496 million)

Brazil holds the second position in the dental implant market in the world, second only to the United States. Geninho Thome is President of Neodent – a privately held dental company specializing in the design development and manufacture of dental implants. The company holds a third of the Brazilian dental implant market.

6. Paulo Sergio Barbanti – R$ 1.39 billion ($594 million)

In 1968, Paulo Sergio Barbanti founded Intermédica – a health business plan with assets including 90 surgical centers, 11 hospitals, eight emergency rooms and a professional network of 5,600 from around the country.

With a total of 3 million beneficiaries, including health and dental plans, Intermédica has a strong presence in São Paulo.

5. Jose Seripieri Filho – R$ 1.51 billion ($645 million)

Jose Seripieri Filho began selling health plans in the late 1980s. His experience in the industry led to the formation of Qualicorp Consultoria e Corretora de Seguros de Vida e Saude Ltda. Jose introduced the business model of making group adhesion health plans possible through partnerships with professional associations, which later on became an industry standard.

4. Francisco Deusmar de Queiros – R$ 2.18 billion ($932 million)

Francisco Deusmar de Queiros owns the second largest pharmacy chain in Brazil in sales, behind only newly consolidated Raia Drogasil. Pay Less, earned $3.2 billion in 2012 and last year was expected to reach revenues of R$ 4 billion and 17,000 employees, according to Forbes Brasil.

3. Jorge Moll Filho – R$ 3.17 billion ($1.35 billion)

Jorge Moll Filho is a Brazilian cardiologist and entrepreneur who founded Cardiolab – a health diagnostics imaging laboratory – in 1977 and was later rebranded as Labs D’Or – a network of health diagnosis centers throughout Rio de Janeiro.

Today, Rede D’Or operates 24 hospitals in several Brazilian cities with more than 4,000 beds. Another four hospitals are in the planning phases.

2. Dulce Pugliese de Godoy Bueno – R$ 4 billion ($1.71 billion)

In 1972, Dulce Pugliese de Godoy Bueno cofounded Amil Participacoes with her former husband Edson de Godo Bueno. With the acquisiotion of a few medical practices, Amil was tuned into a successfully publicly traded health insurer and hospital operator.

Dulce received a PhD in management from McCombs School of Business at the University of Texas at Austin and was assistant professor in the pediatrics department at Universidade Federal do Rio de Janeiro.

1. Edson de Godoy Bueno – R$ 5.79 billion ($2.47 billion)

Edson de Godoy Bueno is Brazil’s richest health care billionaire. In 2012, UnitedHealth Group purchased 90 percent of Brazilian insurer and hospital operator Amil Participacoes for $4.9 billion from Edson, with Edson retaining 10 percent of the share. Edson then went on to buy $470 million worth of UnitedHealth shares and joined the board.

According to Forbes, Edson is the son of a truck driver who decided to become a doctor at the age of 14 while working at a clinic. He later purchased the clinic before getting a medical degree from Universidade Federal do Rio de Janeiro. 

Share article

Jul 28, 2021

5 mins with... Johannes Bhakdi, Quantgene

COVID19
Genomics
AI
biotechnology
3 min
5 mins with... Johannes Bhakdi, Quantgene
Johannes Bhakdi, CEO of Quantgene, tells us about their approach to identifying new COVID-19 variants

Quantgene is a US biotech company that uses AI and the cloud to do genomic testing. It was founded in 2015 to focus on cancer - integrating advanced genomics and molecular diagnostics systems with the cloud and AI systems. 

CEO Johannes Bhakdi tells us Quantgene is the first COVID-19 testing company to fully integrate variant identification - we find out more. 

Given the new Delta and Lambda variants, is the coronavirus mutating at a faster rate than most viruses?
 
The reason SARS-COV2 is mutating on a perceived higher rate is not that the individual viruses mutate at a higher rate, but that the base population infected with the virus is vastly higher. The absolute rate of global mutations is a direct function of how many people have the virus at any given point in time. Since this is a global pandemic, and tens of millions have been infected, we see more mutations. 

That makes it more unpredictable, because any single mutation that has an evolutionary advantage - like the Delta variant - can then take over and spread even faster.  

What is the usual process for testing and analysing viral mutations? 

The most effective tool for analysing mutations is Whole Viral Genome sequencing. It allows you to read out the entire genome of the virus. Once the wet-lab sequencing is complete, we use this information to map it against what is called a "reference genome", meaning the classic SARS-COV2 genome. This allows us to then see any differences between the investigated sample and the baseline genome of SARS COV2. 

We then use these differences to map them against a database of known mutations, like the Delta variant. That way we can see if we are dealing with any known variant, and if we have a new variant at our hands, as well as determine what this new variant does to the spike protein and how likely it is to be a problem with antigens and vaccines, based on the changed protein structure. This last step is not easy and not clear-cut, and there is some speculation into the determination of how problematic the mutated proteins are. 

 What does Quantgene do differently?  

At Quantgene, we are focusing on solving problems for our clients - may it be employers, movie productions or governments. That means we ensure that our client gets the COVID protection they need in the fastest possible time frame and at the highest precision possible - mostly at or below market prices. 

We are bringing together technologies like RT-PCR testing and mutation profiling/sequencing, as well as advanced bioinformatics and computational resources to ensure high-quality results are being delivered seamlessly. 

We are also adding important components such as real-time cloud software and medical services to it. Simply put, we turn the COVID problem into a one-click seamless solution that works better than others, so companies and government clients don't have to deal with laboratories, medical or software providers who point fingers at each other and fail to deliver in time and with high precision. COVID is too dangerous and important to risk falling short.     

Share article